^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EPOR amplification

    i
    Other names: EPOR, Erythropoietin Receptor, EPO-R, Truncated Erythropoietin Receptor
    Entrez ID:
    2057
    Related biomarkers:
    Mutation
    over2years
    Amplified EPOR/JAK2 genes define a unique subtype of acute erythroid leukemia. (PubMed, Blood Cancer Discov)
    These cases were frequently accompanied by gains/amplifications of ERG/ETS2 and associated with a very poor prognosis, even compared with other TP53-mutated AEL. In addition to activation of the STAT5 pathway, a common feature across all AEL cases, these AEL cases exhibited enhanced cell proliferation and heme metabolism and often showed high sensitivity to ruxolitinib in vitro and in xenograft models, highlighting a potential role of JAK2 inhibition in therapeutics of AEL.
    Journal
    |
    TP53 (Tumor protein P53) • JAK2 (Janus kinase 2) • EPOR (Erythropoietin Receptor)
    |
    TP53 mutation • JAK2 mutation • JAK2 amplification • EPOR amplification
    |
    Jakafi (ruxolitinib)